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Our previous study showed that Erythrina variegata L. (EV) inhibited bone loss and improved bone properties in ovariectomised rats. The purpose
of the present study is to investigate the potential mechanism involved in mediating the osteoprotective actions of EV. Female Sprague–Dawley
rats were fed a phyto-oestrogen-free diet and subjected to either ovariectomy or a sham operation. Ovariectomised rats were treated with genistein
(40 mg/kg) as well as low (200 mg/kg), medium (500 mg/kg) or high (1000 mg/kg) doses of EV extract. Bone properties and mRNA expressions
were evaluated by micro-computed tomography and quantitative RT-PCR, respectively. Osteoclast differentiation in RAW 264·7 cells was studied
by tartrate-resistant acid phosphatase (TRAP) staining. High doses of EV could decrease urinary Ca and P excretion, maintain serum Ca and
P level, and exert beneficial effects on the micro-structure and morphology of trabecular bone and cortical bone in ovariectomised rats. EV
suppressed the up-regulation of cathepsin K mRNA and the down-regulation of osteoprotegrin mRNA in the tibia of ovariectomised rats.
TRAP-positive cell numbers were significantly decreased in receptor activator of nuclear factor-kB ligand (RANKL)-induced RAW 264·7 cells
when co-cultured with EV extracts. The present study indicated that the protective effects of EV on bone properties in ovariectomised rats are
likely to be mediated by its inhibitory actions on the process of bone resorption via the suppression of osteoclast differentiation and maturation.
Ovariectomised rats: Osteoporosis: Erythrina variegata L.: Bone resorption
Osteoporosis is a metabolic condition characterised by low
bone mass, deterioration of bone tissues and increased risk
of fracture(1). It is a worldwide public health problem that
creates a significant economic burden on society as well as to
the families of patients who suffer from related fractures(1,2).
Hormone replacement therapy used to be the major regimen
for the prevention and treatment of postmenopausal osteoporosis.
However, with the recent discovery of the association between
hormone replacement therapy and the increased risks in
postmenopausal women to develop breast, endometrial or
ovarian cancers(3 – 5), there is a strong demand to develop
alternative approaches for the management of osteoporosis.
Isoflavones are compounds structurally similar to the mam-
malian oestrogens that are found in plant foods, particularly
soyabeans. They have received considerable attention for
their preventive actions on bone loss(6). Genistein (40,5,7-trihy-
droxyisoflavone) is the major isoflavone found in these
foods(7). The potential efficacy of genistein on bone biology
has been extensively studied and it mainly acts as a selective
oestrogen receptor modulator in vivo and in vitro to exert
beneficial effects on bones(3).
Erythrina variegata L. (EV; Leguminosae), which has been
used as folk medicine in the tropical and subtropical regions,
is known to possess pharmacological activities including anti-
microbial(8), anti-inflammatory(9) and antibacterial effects(10).
Phytochemical work has demonstrated that EV is rich in gen-
istein derivatives(11,12), which is a possible explanation for the
efficacy of using EV extract for the prevention and treatment
of ovariectomy-induced osteoporosis in rats as reported in our
previous study(13). However, the mechanisms by which EV
exerts its protective actions on bone have yet to be studied.
In an attempt to explore the potential mechanism involved
in the osteoprotective effects of EV, the dose-dependent
effects of EV on bone micro-structure and morphology as
well as tibial bone-specific gene expression in ovariectomised
rats, a widely used and well-established animal model for the
study of postmenopausal osteoporosis, was used. In addition,
the in vitro effects of EV on osteoclast differentiation in
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murine macrophage RAW 264·7 cells, which are recognised as
an osteoclast precursor cell line, were also studied.
Materials and methods
Plant material and extraction
The collection and authentication of EV and EV extracts were
done as previously described(13).
Animal study
Sixty virgin female Sprague–Dawley rats, aged 4 months,
were purchased from Guangzhou University of Traditional
Chinese Medicine (Guangzhou, China). Husbandry of the ani-
mals was carried out as previously described(13). All animals
were allowed free access to distilled water and pair-fed a
phyto-oestrogen-low diet (D00031602; Research Diets Inc.,
New Brunswick, NJ, USA), which was prepared according
to the American Institute of Nutrition (AIN)-93M formulation
(D10012M; Research Diets Inc.) except that maize oil was
used instead of soyabean oil. The formulations and estimated
nutrient composition of the experimental diets are referred to
in our previously published paper(14). The acclimatised rats
underwent either bilateral laparotomy (sham; n 10) or bilateral
ovariectomy (n 50). At 1 week after healing from surgical pro-
cedures, the ovariectomised rats were randomly divided into
five groups of ten: vehicle-treated, ovariectomy only (OVX),
genistein-treated (40 mg/kg), low dose of EV extract-treated
(200 mg/kg), medium dose of EV extract-treated (500 mg/kg)
and high dose of EV extract-treated (1000 mg/kg). The EV
extract and genistein were administered daily through a gastric
tube. The dosages of EV used in the present study were chosen
based on the maximal tolerated dose of EV determined in
our previous study(13). The animals were on the diet and treat-
ments for 12 weeks. At the end of the treatment, a 24 h urine
sample was collected. The animals were then killed by with-
drawing blood from the abdominal aorta under light diethyl
ether anaesthesia. Serum was then prepared, and tibiae were
dissected from soft tissue and stored frozen until used for
RNA analysis. The animal study protocols were approved by
the Animal Ethics Committee of The Hong Kong Polytechnic
University.
Chemistry of serum and urine
Serum Ca, P and alkaline phosphatase (ALP), and urine Ca,
P and creatinine were measured as previously described(15).
Analysis of the micro-computed tomography scans
The tibia was scanned with a micro vivaCT 40 system (Scanco
Medical, Bassersdorf, Switzerland). Thirty slices of captured
images were established as the volume of interest. The trabe-
cular bone was separated from the cortical bone by free draw-
ing regions of interest using the software provided with the
scanner. Morphologic measurements for the thirty slices
were performed and the following three-dimensional para-
meters were obtained for the trabecular bone: (1) trabecular
number; (2) trabecular thickness; (3) trabecular separation;
(4) connectivity density (Conn.D). The following diameters
were obtained for the cortical bone: (1) bone surface/bone
volume (BS/BV); (2) Conn. D; (3) structure model index
(SMI), which is a parameter used for the quantification of
the ‘rod-like’ or ‘plate-like’ architecture. The SMI values for
ideal plates and rods are 0 and 3, respectively.
RNA isolation and real-time RT-PCR
The extraction of total RNA from the tibia was performed
according to the TRIzol manufacturer’s protocol. First-strand
cDNA were synthesised from 4mg of total RNA in 20ml reac-
tion volume using the SuperScript First-Strand Synthesis
System (Invitrogen, Carlsbad, CA, USA) and oligo dT
random primers. Real-time PCR was performed in the Light-
Cycler system as described(16). The relative mRNA amount
was normalised to glyceraldehyde 3-phosphate dehydrogenase
mRNA. The PCR primers used in the present study were simi-
lar to those reported in our previous study(17).
Cell culture
The murine macrophage cell line RAW 264·7 was maintained
in phenol red-free Dulbecco’s modified Eagle’s medium con-
taining 5 % charcoal-stripped fetal bovine serum (GIBCO-
BRL, Gaithersburg, MD, USA) and antibiotics at 378C
under 5 % CO2. Cells (1 £ 105) were seeded in a six-well
plate and cultured with receptor activator of nuclear factor-
kB ligand (RANKL) (100 ng/ml) for osteoclast differentiation,
simultaneously supplemented with vehicle or EV extract at the
concentration of 10mg/ml and 100mg/ml in Dulbecco’s modi-
fied Eagle’s medium for 4 d. The concentration of EV was
chosen based on the experimental results reported by Li(18),
who demonstrated that the effective dose range of EV in rat
osteoblast-like cells was from 2 to about 200mg/ml. The
new medium was changed every 2 d.
Tartrate-resistant acid phosphatase staining
Tartrate-resistant acid phosphatase (TRAP) staining was car-
ried out with a TRAP kit (Sigma, St Louis, MO, USA) accord-
ing to the manufacturer’s instructions. Briefly, cells were
washed with PBS and treated with a fixation solution at
room temperature for 5 min. They were then washed with
distilled water and treated with a TRAP reagent at 378C for
20–60 min. After washing with distilled water, the cells
were observed under a microscope. Cells that possessed
three or more nuclei were identified as multinucleated cells.
TRAP-positive and multinucleated cells were counted as
osteoclast-like cells.
Statistical analysis
The data from these experiments were reported as mean values
with their standard errors for each group. All statistical ana-
lyses were performed using PRISM version 4.0 (GraphPad,
San Diego, CA, USA). Inter-group differences were analysed
by one-way ANOVA, and followed by Tukey’s multiple
comparison test as a post hoc test to compare the group
means if overall P,0·05. Differences in P,0·05 were
considered statistically significant.
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Results
Weight gain, and serum and urine chemistry
As shown in Table 1, the weight gain increase in the OVX rats
was more significant than in the sham rats (P,0·05) despite
the pair-feeding of the animals. Treatment of the ovari-
ectomised rats with either the high dose of the EV extract or
genistein reduced the ovariectomy-induced increase in
weight gain (v. OVX rats, P,0·05). Ovariectomy significantly
decreased serum Ca (P,0·01) and P (P,0·05) levels and
increased urinary Ca (P,0·01) and P (P,0·05). In addition,
serum ALP levels increased in response to ovariectomy in
the rats (P,0·01). Treatment with genistein increased serum
Ca (P,0·01) and suppressed urinary Ca (P,0·05) and P
(P,0·05) excretion as well as serum ALP levels (P,0·01)
in the ovariectomised rats. Similarly, treatment with the high
dose of EV increased serum Ca (P,0·05), suppressed urinary
Ca (P,0·05), P (P,0·01) excretion and serum ALP levels
(P,0·01) in the ovariectomised rats. The two lower doses
of EV had no significant effect on serum or urine chemistry
as compared with ovariectomy alone.
Micro-computed tomography analysis of trabecular bone and
cortical bone
Fig. 1 summarises the result of micro-computed tomography
analysis of the tibial trabecular bone and cortical bone
in rats. For the trabecular bone of the tibial head, the trabecu-
lar number, trabecular thickness and Conn.D were signifi-
cantly lower in the OVX group than in the sham group
(Fig. 1(a), (b) and (d); P,0·05), and trabecular separation
was much higher in the OVX group than in the sham group
(Fig. 1(c); P,0·01). Administration of the high dose of EV
(1000 mg/kg) increased trabecular number and Conn.D of
the trabecular bone at the tibial head in the ovariectomised
rats (P,0·05), while genistein treatment did not lead to any
improvement in these parameters of the trabecular bone. In
addition, ovariectomy resulted in a dramatic increase in BS/
BV and SMI and a reduction of Conn.D of the cortical bone
of the tibial diaphysis in the rats. Treatment with genistein sig-
nificantly suppressed the induction of SMI (P,0·015) as well
as the reduction of Conn.D (P,0·01) in the ovariectomised
rats. Treatment with the medium dose of EV suppressed the
ovariectomy-induced increase in SMI level (P,0·01) in the
ovariectomised rats. Treatment of the ovariectomised rats
with the high dose of EV significantly attenuated the changes
in the cortical bone parameters (BS/BV, SMI and Conn.D)
induced by ovariectomy (v. OVX, P,0·05).
Bone-specific gene expressions
Core-binding factor a1 (Cbfa1) is an osteoblast-specific tran-
scription factor that plays an essential role in osteoblastic
differentiation and maturation(17), while cathepsin K (CtsK)
is an osteoclast-specific protein that plays an important role
in the collagen degradation phase of bone resorption(19,20).
As expected, the expression of Cbfa1 mRNA was suppressed
(Fig. 2(a); P,0·05) and the expression of CtsK mRNA was
induced (Fig. 2(b); P,0·05) in rat tibia in response to ovari-
ectomy. Treatment of the ovariectomised rats with genistein
reversed the changes in Cbfa1 and CtsK mRNA in tibia
induced by ovariectomy (P,0·01). In contrast, treatment of
the ovariectomised rats with EV extract did not alter Cbfa1
mRNA expression in tibia, suggesting that EV extract might
not alter bone formation in vivo. Furthermore, treatment of
the ovariectomised rats with the medium or high dose of EV
significantly down-regulated CtsK mRNA expression in
tibia, suggesting that EV extract might suppress bone resorp-
tion in vivo (P,0·05).
Osteoprotegerin (OPG) and RANKL, which are produced
by osteoblasts, play an essential role in controlling the process
of osteoclastogenesis(16). mRNA expression of OPG (Fig. 3(a);
P,0·01) as well as the ratio of OPG:RANKL mRNA
expression (Fig. 3(c); P,0·05) in tibia decreased in response
to ovariectomy as compared with the sham rats. Treatment of
the ovariectomised rats with genistein (P,0·05) or EV
extracts at all three doses (P,0·01) induced the expression
of OPG in tibia, resulting in an increase in the OPG:RANKL
ratio (P,0·05) back to the sham level. However, RANKL
mRNA expressions were not altered by ovariectomy or treat-
ment with either genistein or EV extract.
Tartrate-resistant acid phosphatase-positive cells
To determine if EV extract can directly regulate the process
of osteoclast formation, pre-osteoclastic RAW 264·7 cells
Table 1. Effects of Erythrina variegata L. (EV) on weight gain and levels of biochemical markers in serum and urine of ovariectomised rats
(Mean values with their standard errors for nine or ten rats per group)
Weight gain (g) Serum ALP (U/l) Serum Ca (mg/l) Serum P (mg/l)
Urine Ca:creatinine
(mg/mg)
Urine P:creatinine
(mg/mg)
Group Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Sham 34·4 4·0 21·75 1·91 147·9 5·6 54·8 2·6 0·011 0·002 0·15 0·03
OVX 59·4† 6·6 64·70†† 3·77 102·3†† 4·9 45·0† 2·5 0·023†† 0·002 0·23† 0·02
Genistein 36·5* 6·9 48·13** 3·81 126·5** 5·3 50·6 2·1 0·015* 0·003 0·16* 0·02
EV-L 55·7 5·6 49·47* 3·98 109·6 3·0 49·1 1·0 0·022 0·001 0·18 0·02
EV-M 46·6 5·5 53·91 3·42 98·9 4·5 50·8 3·0 0·021 0·002 0·16* 0·02
EV-H 38·2* 5·4 45·34** 3·64 122·9* 8·0 53·4 2·5 0·014* 0·002 0·13** 0·02
ALP, alkaline phosphatase; OVX, ovariectomised only (vehicle-treated); EV-L, low dose of EV extract; EV-M, medium dose of EV extract; EV-H, high dose of EV extract.
Mean value was significantly different from that of the OVX group: * P,0·05, ** P,0·01.
Mean value was significantly different from that of the sham-operated group: †P,0·05, ††P,0·01.
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stimulated with RANKL were co-treated with the vehicle, or
EV extract at 10mg/ml or 100mg/ml for 4 d. The present
results indicated that TRAP-positive and multinucleated
cells that possessed three or more nuclei were formed in
RAW 264·7 cells in response to the RANKL stimulation,
thus confirming the formation of osteoclasts (Fig. 4). EV at
100mg/ml, but not at 10mg/ml, dramatically reduced the
number of TRAP-positive cells (P,0·05) when compared
with the vehicle-treated cells. These results indicated that
EV at high concentrations could directly suppress the process
of osteoclast formation in vitro.
Discussion
The present study demonstrated that ovariectomy induced
higher weight gain, increases in serum ALP levels, urinary
Ca and P excretion, and decreases in serum Ca and P levels,
suggesting that ovariectomy led to changes in energy metab-
olism as well as bone and mineral metabolism. These changes
are consistent with the results of our previous animal
studies(13,15) as well as other clinical studies(21,22). The ovari-
ectomy-induced changes of biochemistry were simultaneously
accompanied with bone loss and bone micro-architectural
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Fig. 1. Micro-computed tomography bone parameters of trabecular bone (a–d) and cortical bone (e–g) of tibial proximal metaphysis and diaphysis, respectively,
in sham-operated, ovariectomised only (vehicle-treated) (OVX), and genistein- (Gen) or Erythrina variegata L. (EV)-treated ovariectomised rats. EV-L, low dose of
EV extract; EV-M, medium dose of EV extract; EV-H, high dose of EV extract; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation;
Conn.D, connectivity density; BS/BV, bone surface/bone volume; SMI, structure model index. Values are means (n 10 per group), with standard errors rep-
resented by vertical bars. Mean value was significantly different from that of the OVX group: * P,0·05, ** P,0·01. Mean value was significantly different from that
of the sham-operated group: † P,0·05, †† P,0·01.
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deterioration in both the trabecular bone and cortical bone.
All these pathological alterations, including alterations in
chemical markers and bone properties, demonstrated the
onset and development of postmenopausal osteoporosis
induced by oestrogen deficiency.
In the present study, EV extract could effectively inhibit the
high rate of urinary Ca and P excretion in the ovariectomised
rats and restore serum Ca and P levels to the normal level.
Moreover, EV extract suppressed high bone turnover rate in
the ovariectomised rats as indicated by a reduction in serum
ALP level in the EV-treated groups as compared with that
of the OVX rats. Therefore, EV might protect oestrogen-
deficient animals from postmenopausal bone loss by reducing
urinary mineral excretion, maintaining serum mineral levels as
well as normal rate of bone turnover.
The results indicated that the micro-architecture of the
trabecular bone at the tibial metaphysis was improved in the
ovariectomised rats in response to the 12-week treatment of
orally administrated EV extracts. These results were in agree-
ment with the histomorphometric analysis performed on the
same bone site in our previously reported study(13). In
addition, EV extract decreased the value of SMI at the tibial
diaphysis in the ovariectomised rats in a dose-dependent
manner. Thus, EV helped to prevent the ovariectomy-induced
formation of rod-like structures in the cortical bone of rat
tibia. Furthermore, the cortical bone parameters of the ovari-
ectomised rats treated with the high dose of EV extract,
such as BS/BV and Conn.D, were restored almost to the
level found in the tibial cortical bone of the sham-operated
rats. These results suggest that EV extract could improve
bone structure and morphology at both the trabecular and cor-
tical bones in the ovariectomised rats. The improvement that
EV brought to the bone structure and morphology of the
tibial mid-shaft might account for the increase in bone biome-
chanical strength observed in our earlier report(13).
Genistein (40 mg/kg) did not display any beneficial effects
against the ovariectomy-induced deterioration of the trabecu-
lar bone of rats in the present study. Similar results had
been observed and reported in our recently published
paper(14) in which genistein (2·5 mg/d) showed no effects on
the bone properties at the tibial head of ovariectomised
mice. As the dosage of genistein applied in both studies
was comparable after the correction of animal species,
we concluded that crude isoflavone extracts such as EV
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Fig. 2. Expressions of core-binding factor a1 (Cbfa1; a) and cathepsin K
(CtsK; b) mRNA in the tibia of sham-operated, ovariectomised only (vehicle-
treated) (OVX), and genistein- (Gen) or Erythrina variegata L. (EV)-treated
ovariectomised rats. EV-L, low dose of EV extract; EV-M, medium dose of
EV extract; EV-H, high dose of EV extract; GAPDH, glyceraldehyde 3-phos-
phate dehydrogenase. Values are means (n 10 per group), with standard
errors represented by vertical bars. Mean value was significantly different
from that of the OVX group: * P,0·05, ** P,0·01. † Mean value was signifi-
cantly different from that of the sham-operated group (P,0·05).
(a)
Sham OVX Gen EV-L EV-M EV-H
0·00
0·25
0·50
0·75
1·00
††
*
** ** **
O
P
G
:G
A
P
D
H
(b)
Sham OVX Gen EV-L EV-M EV-H
0·0
0·1
0·2
0·3
0·4
0·5
0·6
0·7
R
A
N
K
L:
G
A
P
D
H
(c)
Sham OVX Gen EV-L EV-M EV-H
0
1
2
†
* * * *
O
P
G
:R
A
N
K
L
Fig. 3. Expressions of osteoprotegerin (OPG; a) mRNA and receptor activa-
tor of nuclear factor-kB ligand (RANKL; b) mRNA and the OPG:RANKL ratio
(c) in the tibia of sham-operated, ovariectomised only (vehicle-treated)
(OVX), and genistein- (Gen) or Erythrina variegata L. (EV)-treated ovari-
ectomised rats. EV-L, low dose of EV extract; EV-M, medium dose of EV
extract; EV-H, high dose of EV extract; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase. Values are means (n 10 per group), with standard errors
represented by vertical bars. Mean value was significantly different from
that of the OVX group: * P,0·05, ** P,0·01. Mean value was significantly
different from that of the sham-operated group: † P,0·05, †† P,0·01.
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extracts and Novasoy(14) were more superior to the pure
isoflavone compound genistein in the prevention of
ovariectomy-induced osteoporosis in animals. However, it
should be noted that a higher dosage (1000 mg/kg) of EV is
needed to achieve efficacy similar to that of Novasoy at
400 mg/kg(14). One possible explanation for this observation
might be that the amounts of isoflavones present in the EV
(10 %) and Novasoy (40 %) extracts were different. In addition,
our previous in vitro data indicated that the isoflavone
compounds in EV extracts, which were mainly genistein deri-
vatives, produced more dramatic stimulation on osteoblastic
proliferation, differentiation and mineralisation than genistein(11).
Collectively, these results suggest that EV has a higher
potential activity on preserving bone mass than genistein.
Further studies are needed to verify the protective effects of
EV extracts on bones in humans and to develop chemical
methods to purify more isoflavones found in EV extracts.
To investigate the potential mechanism involved in the
osteoprotective effects of EV, the mRNA expressions of an
osteoblast-specific gene (cbfa1), an osteoclast-specific gene
(CtsK), as well as the OPG–RANKL system in rat tibia,
were studied. The present results indicated that EV extract
did not alter the Cbfa 1 mRNA expression in the tibia of the
ovariectomised rats, suggesting that EV extract might not
stimulate bone formation in vivo. The present study showed
that EV dose-dependently down-regulated mRNA expression
of CtsK, suggesting that it could inhibit osteoclast-mediated
bone resorption, at least partially by the inhibition of CtsK
expression. This finding also explains the reduced excretion
of urinary deoxypyridinoline, the degraded product of col-
lagen, in ovariectomised rats in our previous report(13). OPG
and RANKL play an essential role in regulating the process
of osteoclastogenesis. RANKL binds to the transmembrane
receptor RANK expressed on the surface of osteoclast precur-
sors and osteoclasts, and is involved in the differentiation and
fusion of osteoclast precursor cells, whereas OPG acts as a
decoy receptor by blocking the interaction of RANKL with
its functional receptor RANK(23). The present study is the
first to report that EV could up-regulate the expression of
OPG and increase the OPG:RANKL ratio; thus, it inserts
protective effects on bone mass by the inhibition of
OPG–RANKL-regulated osteoclastogenesis.
TRAP is considered a histochemical marker of osteoclasts
and is highly expressed in osteoclasts in normal condition(24).
Our in vitro study using RAW 264·7 cells clearly demon-
strated that EV (100mg/ml) could significantly reduce the
number of TRAP-positive cells in RANKL-stimulated cells.
These results indicated that EV extract could directly inhibit
the process of osteoclast differentiation and maturation.
They provide additional evidence to support the fact that EV
extract exerts its bone-protective effects by the inhibition of
the process of bone resorption. Together with our previous
in vitro studies of EV on osteoblasts(11,12), we conclude that
EV can act on both osteoblasts and osteoclasts in vitro, but
the major actions in vivo seem to be through the inhibition
of bone resorption.
Taken together, the present study clearly demonstrated that
EV extract is effective in improving bone properties and redu-
cing urinary mineral excretion in oestrogen-deficient rats.
Most importantly, our in vivo and in vitro results clearly
demonstrated that EV extract could suppress the process of
bone resorption through its direct actions on the inhibition
of osteoclast-specific gene expression and the process of
osteoclast formation. Further study is needed to identify the
active components and compounds in EV that might account
for its inhibitory activity on bone resorption. Nevertheless,
the present results support the use of EV extract as an alterna-
tive regimen for the management of postmenopausal
osteoporosis.
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264·7 cells in the absence (control; Con) or presence of Erythrina variegata L. (EV) extracts at 10mg/ml and 100mg/ml for 4 d. Three separate experiments were
performed with four repeated wells for each group. MNC, multinucleated cells; ! ,TRAPþ MNC. Values are means with their standard errors. * Mean value was
significantly different from that of the control treatment (P,0·05).
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